TERPS Trial for de Novo Oligometastic Prostate Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorUniversity of Maryland, Baltimore
About this trial
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Eligibility criteria
Qualifiers
Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone or soft tissue (with at least one bone metastasis) develop within the past 6-months that are seen on imaging. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or PSMA PET-CT scan.
CT or MRI scan within 6 months of enrollment
Bone scan within 6 months of enrollment
Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)
Disqualifiers
Castration-resistant prostate cancer (CRPC).
Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy
Spinal cord compression or impending spinal cord compression.
Suspected pulmonary and/or liver metastases (greater >10 mm in largest axis).
Trial design
Treatments tested in this trial
- Prostate radiation (XRT)
- Systemic Therapy
- Stereotactic ablative radiation therapy (SABR)
Treatment groups
122 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov